The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing
Open accessAbstract
The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is evidence that the inflammatory serological markers that are usually associated with bacterial infection, such as raised procalcitonin and C-reactive protein, may appear in patients with COVID-19 without a corresponding bacterial co-infection occurring.12 , 13”
From Co-infections in people with COVID-19: a systematic review and meta-analysis. (2020) · cites this paper as [12]
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Clinical characteristics of 2019 novel coronavirus infection in ChinaPreprint
Guan, W., Ni, Z., Hu, Y., et al. (2020) · medRxiv · doi:10.1101/2020.02.06.20020974 · Cited by 1,485
Self-citationAssiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
Wong, C. K., LAM, C. W. K., Wu, A. K. L., Ip, W., Lee, N. L. S., Chan, I., Lit, L. C. W., Hui, D. S. C., Chan, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,270
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam
Lan, P. T., Nguyễn, T. V., Lương, Q. C., Nguyen, T. V., Nguyen, H. T., Le, H. Q., Nguyen, T. T., Cao, T. M., & Pham, Q. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001272 · Cited by 1,164
Flagged first, then by citations
Research works printed but not linked: 2
- General Office of the National Health and Family PlanningCommission, 2020, Diagnosis and treatment of novel coronavirus pneumonia (trial version 5), Chin J Integr Med, 3
- Wang F, 2018, Effects of matrine combied with baicalin on mouse pneumonia induced by LPS, Chin Pharmacol Bull, 8, 1105
Cited by
Sorted by citations
Lechien, J. R., Chiesa-Estomba, C. M., De Siati, D. R., Horoi, M., Le Bon, S. D., Rodriguez, A., Dequanter, D., Blecic, S., El Afia, F., Distinguin, L., et al. (2020) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-020-05965-1 · Cited by 2,668
Co-infections in people with COVID-19: a systematic review and meta-analysis.
Lansbury, L., Lim, B., Baskaran, V., & Lim, W. S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.046 · Cited by 1,619
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19
Azkur, A. K., Akdiş, M., Azkur, D., Sokołowska, M., van de Veen, W., Brüggen, M., O’Mahony, L., Gao, Y., Nadeau, K. C., & Akdiş, C. A. (2020) · Allergy · doi:10.1111/all.14364 · Cited by 1,149
Troyer, E. A., Kohn, J. N., & Hong, S. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.027 · Cited by 964
Huang, I., Lim, M. A., & Pranata, R. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.018 · Cited by 974
Metadata
- Authors
- Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., Lang, C., Huang, D., Sun, Q., Xiong, Y., Huang, X., Lv, J., Luo, Y., Shen, L., Yang, H., Huang, G., & Yang, R.
- Affiliations
- Chongqing University (CN)
- Chongqing Medical University (CN)
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
- Corresponding author
- Zheng, Yu
- Li, Boqun
- Hu, Yanjun
- ORCID
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2020-04
- Volume
- 92
- Issue
- 7
- Pages
- 797-806
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- PMC
- PMC7228368
- OpenAlex
- W3012673820
- Cited by
- 982
- References
- 27
- Citations by year
- 2026: 2 · 2025: 13 · 2024: 40 · 2023: 75 · 2022: 125 · 2021: 299 · 2020: 427
- FWCI
- 30.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Medical Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundamental Research Funds for the Central Universities (2020CDJYGRH-YJ03)
- National Social Science Foundation (15BGL191)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- COVID-19 pandemic, SARS-CoV-2, clinical features, lopinavir/ritonavir, ritonavir, traditional Chinese medicine, antiviral therapy, corticosteroids, antibiotic therapy, interferon, viral pneumonia, chest CT findings, ground-glass opacities, lymphocyte count, D-dimer, lactate dehydrogenase, C-reactive protein, comorbidities, hospitalized patients
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Testing, Adolescent, Adrenal Cortex Hormones, Adult, Aged, Anti-Bacterial Agents, Antiviral Agents, Cardiovascular Diseases, China, Cough, Diabetes Mellitus, Drug Combinations, Drugs, Chinese Herbal, Fatigue, Female, Fever, Humans, Interferons, Male, Middle Aged, Neoplasms, Pneumonia, Viral, Retrospective Studies, Severity of Illness Index, Tomography, X-Ray Computed, Biomarkers, Coronavirus Infections, Clinical Laboratory Techniques, Ritonavir, Diabetes Complications, Pandemics, Lopinavir
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
